3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
20
Mycosis Fungoides
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Lymphoma, Non-Hodgkin
16
Lymphoma, Mantle-Cell
16
Lymphoma, Large-Cell, Immunoblastic
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, Follicular
16
Lymphoma, B-Cell, Marginal Zone
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Hodgkin Disease
16
Burkitt Lymphoma
16
Sezary Syndrome
15
Leukemia, Myeloid, Acute
15
Multiple Myeloma
14
Lymphoma
14
Leukemia, Myeloid, Accelerated Phase
14
Congenital Abnormalities
14
Leukemia, Myeloid, Chronic-Phase
13
Myeloproliferative Disorders
12
Primary Myelofibrosis
11
Myelodysplastic Syndromes
11
Leukemia, Myelomonocytic, Chronic
11
Leukemia
11
Blast Crisis
11
Recurrence
10
Neoplasms, Plasma Cell
10
Waldenstrom Macroglobulinemia
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Large-Cell, Anaplastic
9
Interventions
Brentuximab Vedotin
4
Bexarotene
2
iratumumab
1
Vitamin B 12
1
Salvia hispanica seed extract
1
Methotrexate
1
Lenalidomide
1
Folic Acid
1
Cholecalciferol
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Methotrexate
×
Dermatologic
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts